• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Revvity Inc.

    5/30/25 8:00:26 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    SD 1 d927602dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM SD

    SPECIALIZED DISCLOSURE REPORT

     

     

    Revvity, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Massachusetts   001-05075   04-2052042

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    77 4th Avenue, Waltham, Massachusetts   02451
    (Address of Principal Executive Offices)   (Zip Code)

    John L. Healy (781) 663-6900

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

      ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

      ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended      .

     

     
     


    Section 1 – Conflict Minerals Disclosure

    Item 1.01 – Conflict Minerals Disclosure and Report

    The Conflict Minerals Report for the calendar year ended December 31, 2024, filed herewith as Exhibit 1.01, is available at www.revvity.com under “Social”.

    Item 1.02 – Exhibit

    Exhibit 1.01 – Conflict Minerals Report of Revvity, Inc. for the calendar year ended December 31, 2024.

    Section 2 – Resource Extraction Issuer Disclosure

    Item 2.01 – Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

    Item 3.01 – Exhibits

    Exhibit 1.01 – Conflict Minerals Report of Revvity, Inc. for the calendar year ended December 31, 2024.

     

    2


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

        REVVITY, INC.
    Date: May 30, 2025     By:  

    /s/ Joel S. Goldberg

        Joel S. Goldberg
        Senior Vice President, Administration, General Counsel and Secretary

     

    3

    Get the next $RVTY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Revvity upgraded by UBS with a new price target

      UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

      5/1/25 7:42:49 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity downgraded by Bernstein with a new price target

      Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

      1/10/25 8:41:17 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity upgraded by BofA Securities with a new price target

      BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

      12/13/24 8:43:02 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    SEC Filings

    See more
    • SEC Form 11-K filed by Revvity Inc.

      11-K - REVVITY, INC. (0000031791) (Filer)

      6/20/25 2:18:15 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Revvity Inc.

      SD - REVVITY, INC. (0000031791) (Filer)

      5/30/25 8:00:26 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Revvity Inc.

      10-Q - REVVITY, INC. (0000031791) (Filer)

      5/6/25 4:07:57 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 4:30:07 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Revvity Inc.

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:28:28 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Revvity Inc.

      SC 13G - REVVITY, INC. (0000031791) (Subject)

      11/14/24 1:22:34 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $RVTY
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2025

      Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continu

      4/28/25 6:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity Board Declares Quarterly Dividend

      The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detec

      4/24/25 4:05:00 PM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Revvity to Hold Earnings Call on Monday, April 28, 2025

      Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows

      4/3/25 8:00:00 AM ET
      $RVTY
      Biotechnology: Laboratory Analytical Instruments
      Industrials